相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Evaluation of Bifunctional Chelates for the Development of Gallium-Based Radiopharmaceuticals
Cara L. Ferreira et al.
BIOCONJUGATE CHEMISTRY (2010)
A modular IgG-scFv bispecific antibody topology
Kelly Davis Orcutt et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
John M. Pagel et al.
BLOOD (2009)
Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma
Robert M. Sharkey et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- and 90Y-Ibritumomab Tiuxetan
Darrell R. Fisher et al.
JOURNAL OF NUCLEAR MEDICINE (2009)
177Lu- labeled MOv18 as compared to 131I- or 90Y-labeled MOv18 has the better therapeutic effect in eradication of alpha folate receptor-expressing tumor xenografts
Alberto Zacchetti et al.
NUCLEAR MEDICINE AND BIOLOGY (2009)
Synthesis and evaluation of technetium-99m-and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA)
Sangeeta R. Banerjee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
DOTA-PESIN, a DOTA-conjugated bombesin derivative designed for the imaging and targeted radionuclide treatment of bombesin receptor-positive tumours
Hanwen Zhang et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy
Preeti Misra et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs:: Side-by-side comparison of the CB-TE2A and DOTA chelation systems
Jered C. Garrison et al.
JOURNAL OF NUCLEAR MEDICINE (2007)
Cardiovascular safety of gadoterate meglumine (Gd-DOTA)
Philippe Bourrinet et al.
INVESTIGATIVE RADIOLOGY (2007)
An HPLC/mass spectrometry platform for the development of multimodality contrast agents and targeted therapeutics: prostate-specific membrane antigen small molecule derivatives
Valerie Humblet et al.
CONTRAST MEDIA & MOLECULAR IMAGING (2006)
A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted Radioimmunotherapy of hematologic malignancies
YK Lin et al.
CANCER RESEARCH (2006)
Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys
JS Jaggi et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Differences in biodistribution between 99mTc-depreotide, 111In-DTPA-octreotide, and 177Lu-DOTA-Tyr3-octreotate in a small cell lung cancer animal model
A Schmitt et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
Recent advances in pretargeted radioimmunotherapy
A Gruaz-Guyon et al.
CURRENT MEDICINAL CHEMISTRY (2005)
MicroPET and autoradiographic imaging of breast cancer alpha(v)-integrin expression using F-18- and Cu-64-labeled RGD peptide
XY Chen et al.
BIOCONJUGATE CHEMISTRY (2004)
Physical models and dose factors for use in internal dose assessment
MG Stabin et al.
HEALTH PHYSICS (2003)
A streptavidin-biotin binding system that minimizes blocking by endogenous biotin
KJ Hamblett et al.
BIOCONJUGATE CHEMISTRY (2002)
Current and potential therapeutic uses of lanthanide radioisotopes
CS Cutler et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2000)
Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity
DB Axworthy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
